Skip to main content
Equibles
PASG logo

PASG · Passage BIO, Inc. · Metrics

Track PASG — free

Use PASG with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PASG.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.01 +0.01 (+0.25%) At close · Nov 12 Q4 2022 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As a result, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.”
View the 10-Q filed Aug 10, 2026
Market Cap
$12.90M
Shares
3.22M
Volume · Nov 12 12.63K Avg daily vol (3M) 20.62K

PASG metrics

61 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.01
Market cap
$12.90M

Price action

23 metrics
Price change (1W)
+14.0%
Price change (30D)
+9.9%
Price change (3M)
-12.9%
Price change (6M)
-27.5%
Price change (YTD)
-66.1%
Price change (1Y)
-48.1%
Trailing year
Price change (5Y)
—
52-week high
$19.85
52-week low
$3.32
Change from 52-week high
-79.8%
Change from 52-week low
+20.5%
Annualized volatility
115.0%
Annualized volatility (3M)
88.4%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
2.2
RSI (14D)
55.4
Price vs SMA 50
-3.2%
Price vs SMA 200
-32.0%
Avg volume (3M)
20,515
Relative volume
1.4
Average dollar volume
$90,039

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
3.22M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
257.4
reciprocal yield 0.4%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-257.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-05-13

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$35.31M
Net income (TTM)
−$33.08M
Trailing 12 months
Diluted EPS (TTM)
$-10.35
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-11.04
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-10.34
Operating cash flow per diluted share (TTM)
$-10.19
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$4.49
Stock compensation per diluted share (TTM)
$0.63
Book value per share
$5.89

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-66,164.0%
Return on assets
-159.1%
Debt / equity
—
Current ratio
1.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$20.16M
Latest balance sheet
Cash & equivalents
$20.16M
Total assets
$20.79M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$32.65M
Capital expenditures (TTM)
—
R&D (TTM)
$14.35M
SG&A (TTM)
—
Stock compensation (TTM)
$2.00M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
29
13F filer change QoQ
-6
Institutional ownership
43.5%
Conviction holders (share of 13F filers)
3.4%
Crowding (high-turnover and private-fund holders)
31.0%
Private-fund adviser ownership
30.3%
Active holders' share change QoQ
-23.9%
Holder tenure
12.0
Price vs estimated holder cost
-66.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
4.5%

Short interest

3 metrics
Short interest
1.5%
Latest settlement · 4.0 days to cover
Days to cover
4.0d
Short-squeeze score
39 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1787297 CUSIP 702712209 13F (30d) 25 filings 14 filers Visit website Investor relations